Search results
AbbVie’s Humira loss of exclusivity has been a missed opportunity for competitors
Pharmaceutical Technology· 4 days agoAbbVie has maintained a strong position within the immunology space for the past few years, largely...
Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex
BioPharma Dive· 5 days agoThe startup says drugs AbbVie abandoned last year could form a combination regimen with “superior...
AbbVie looks to add a ninth indication for JAK inhibitor Rinvoq
Pharmaceutical Technology· 6 days agoAbbVie is set to expand the indication list for its immunology blockbuster, Rinvoq (upadacitinib)....
Boehringer Ingelheim offers Humira biosimilar at 92% discount
Pharmaceutical Technology· 2 days agoBoehringer Ingelheim will sell an unbranded version AbbVie’s reference drug at a 92% discount to...
Boehringer cuts price of Humira biosimilar in bid to build use
BioPharma Dive· 3 days agoBoehringer Ingelheim will sell an unbranded version of its Humira biosimilar at a 92% discount to...
Boehringer-GoodRx partner to offer Humira rival at 92% discount - ET HealthWorld | Pharma
The Economic Times· 2 days agoLondon: A close copy version of Abbvie's blockbuster arthritis drug Humira will be available at a 92...
Two drugmakers file lawsuits to block Kansas’ attempt to tinker with discount drug program
Kansas Reflector· 5 days agoA pair of drugmakers filed federal lawsuits challenging constitutionality of a new Kansas law...
Trump promises to cut corporate tax rate to 15% if elected as US President
Financial Express· 4 days agoTrump's victory could boost stocks, but bonds' outlook is skewed due to potential corporate tax...